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Abstract 
Background: To reduce the duration of neutropenia after conditioning chemotherapy 
and autologous peripheral blood stem cell transplantation (APBSCT), granulocyte-
colony stimulating factors (G-CSF) are commonly administered.  
Patients and Methods: We retrospectively evaluated the impact of pegfilgrastim 
compared to filgrastim on neutrophil engraftment, hospital stay and supportive 
measures in patients with multiple myeloma (MM) after conditioning with Melphalan 
200 (Mel200) followed by APBSCT.  
Results: Ninety-two APBSCT after Mel200 treatment were performed in 72 patients 
between January 2006 and December 2009 at our institution. Patients received 
either single-dose pegfilgrastim (n=46; 50%), or daily filgrastim (n=46; 50%) after 
APBSCT (median duration of filgrastim use, 9 days; range, 3-14 days). Duration of 
neutropenia grade IV was shorter with pegfilgrastim compared with filgrastim 
(median, 5 days (range, 3-14 days) versus 6 days (range, 3-9 days), p=0.0079). The 
length of hospitalization differed significantly (pegfilgrastim (median, 14.5 days; 
range, 11-47 days) versus filgrastim (median, 15.5 days; range, 12-64 days), 
p=0.024). Pegfilgrastim treated patients had less red blood cell transfusions (median, 
0 transfusions (range, 0-10) versus 0.5 transfusions (range, 0-9), p=0.00065). 
Pegfilgrastim was associated with reduced cost of the treatment procedure compared 
with filgrastim (p=0.031).  
Conclusion: Pegfilgrastim appears to be at least equivalent to filgrastim without 
additional expenditure in myeloma patients treated with Mel200 and APBSCT. 
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List of abbreviations 
MM   multiple myeloma 
APBSCT  autologous peripheral blood stem cell transplantation 
G-CSF  granulocyte-colony stimulating factor 
Mel200  high dose melphalan (200 mg/m2) 
ANC   absolute neutrophil count 
i.v.   intravenous 
ICU   intensive care unit 
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Introduction 
Autologous peripheral blood stem cell transplantation (APBSCT) is an 
established treatment modality for patients with multiple myeloma (MM) [1-2]. 
Infectious complications may occur during a period of severe neutropenia that put the 
patients at risk for morbidity and mortality after high-dose chemotherapy [3-5]. To 
reduce the time to neutrophil engraftment and eventually the risk for neutropenic 
fever, many transplantation centers use granulocyte-colony stimulating factors (G-
CSF) after APBSCT, although data on their impact on relevant clinical parameters as 
duration and onset of fever, length of hospital stay, the use of antibiotics, infectious 
mortality and ultimately treatment cost are still ambiguous [6-9]. This is also reflected 
by the differing recommendations of American and European guidelines. The former 
recommend the use of G-CSF after APBSCT, while the latter classify their use as 
controversial for this indication [10-11]. 
Filgrastim (Neupogen©, Amgen) is the G-CSF most commonly used in this 
setting. Due to its short half-life, daily injections are necessary until neutrophil 
recovery has been documented for at least three consecutive days. In the past, our 
center had reported on the superiority of filgrastim treatment after autologous bone 
marrow transplantation compared with no administration of filgrastim with respect to 
neutrophil recovery and duration of neutropenic fever [12].  
Pegfilgrastim (Neulasta©, Amgen) is the pegylated form of filgrastim. Due to 
the long-term formulation it has the advantage over filgrastim of a single application 
after the ablative chemotherapy, thus improving patient comfort. The efficacy of 
pegfilgrastim has already been shown in patients treated with conventional doses of 
chemotherapy by reducing the duration of neutropenia and the need for antibiotic 
treatment [13-15]. Until now, only a few studies with small or heterogenous patient 
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collectives have been performed which assess the impact of pegfilgrastim in this 
setting [16-20]. The most relevant limitation of the data available in the literature is 
that patients with different diseases treated with different conditioning regimens were 
analyzed together, without taking into account that patient collectives likely differ in 
terms of chemotherapy associated toxicity and the necessary patient care [21-23]. 
Here we report on the efficacy of pegfilgrastim compared with filgrastim in 
patients with multiple myeloma receiving Melphalan 200 (Mel200) and APBSCT, with 
special emphasis on treatment cost during the post-transplant period. 
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Patients and Methods 
We performed a ‘per transplant’ analysis of myeloma patients receiving high-
dose chemotherapy with Mel200 and subsequent APBSCT during the last four years 
(2006 – 2009) at our center. The analysis was approved by our local ethical 
committee. 
Patients received either pegfilgrastim or daily filgrastim after APBSCT. From 
January 2006 to December 2007 patients routinely received filgrastim. Expecting 
benefits regarding patient comfort and safety we decided by late 2007 to implement a 
practice change, accordingly from January 2008 to December 2009 pegfilgrastim 
was generally administered after APBSCT. No other practice changes within the 
transplantation programme were applied during the whole analysis period. 
Pegfilgrastim was administered as a single fixed dose of 6 mg subcutaneously at day 
+1 after stem cell reinfusion. Filgrastim was given at a dose of 5 µg/kg body weight 
subcutaneously once daily, starting at day +5 after stem cell reinfusion, until the 
absolute neutrophil count (ANC) was ≥ 0.5 x 109 cells/L for at least three consecutive 
days. This analysis includes all patients with multiple myeloma who received Mel200 
during this period. Patients treated with APBSCT for other diseases or myeloma 
patients who received a reduced conditioning chemotherapy (i.e. Mel140) were 
excluded from this analysis.  
The medical records of the patients and our prospectively collected 
transplantation database were screened for hospital stay, appearance and duration 
of neutropenic fever, the use of intravenous antibiotics and the need for red blood cell 
and platelet transfusions during hospital stay and compared between the groups. 
Neutropenia was defined as ANC below 0.5 x 109 cells/L. Fever was defined 
as body temperature ≥ 38.4°C. Every day of fever was considered for analysis when 
a body temperature over this cut-off was documented in the patient charts. 
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Hospitalization time in this analysis was defined as time from the day of stem cell 
reinfusion (day 0) to the day of patient’s discharge.  
 
Statistical analyses 
Statistical methods comparisons of patient characteristics were made using 
either a Mann-Whitney U-test, or a Fisher’s exact test, as appropriate. Continuous 
clinical outcomes are presented as median (range), and compared using the Mann-
Whitney U-test, while binary clinical outcomes are presented as a percentage, and 
compared using Fisher’s exact test. Cost analysis is based on the average cost of 
blood products, average length of stay, and on average cost of filgrastim or 
pegfilgrastim per patient (compared with the Kruskal-Wallis test). 
All analysis was performed in the R programming language [24]. 
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Results 
Patient demographics 
Between January 2006 and December 2009, a total of 122 APBSCT with 
subsequent G-CSF support were performed in MM patients at our institution. Ninety-
two (75%) APBSCT were performed with Mel200 in 72 patients and were included 
into this analysis. During this time period, 67 (73%) were first APBSCT, and 25 (27%) 
were second APBSCT. There was an equal balance between patients receiving 
either single-dose pegfilgrastim or filgrastim after APBSCT with 46 (50%) cases per 
treatment group.  Filgrastim was applied after APBSCT for a median of 9 days 
(range, 3 – 14 days). The patient characteristics were well balanced between the two 
groups including the dose of CD34+ stem cells reinfused and the number of APBSCT 
performed (Table 1). 
 
Efficacy 
Neutrophil engraftment was faster with pegfilgrastim than with filgrastim 
(median 9 days (range, 8-18) versus 10 days (range, 8-12), p=0.032), and 
accordingly, the median duration of neutropenia grade 4 was significantly shorter in 
the former patients (median 5 days (range, 3-14) versus 6 days (range, 3-9), 
p=0.0079). No difference between the two groups was observed regarding the 
duration of thrombocytopenia grade 4 (median, 3.5 days (range, 0-15) versus 3 days 
(range, 0-10); p=0.39). In addition, less red blood cell transfusions were necessary in 
the pegfilgrastim treated patients (median, 0 transfusions (range, 0-10) versus 0.5 
transfusions (range, 0-9); p=00065). No significant differences were observed 
regarding the number of platelet transfusions, the duration of fever and the duration 
of intravenous antibiotic treatment between the two groups (Table 2).  
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Overall, 23 (50%) patients receiving filgrastim needed red blood cell 
transfusions during their hospital stay compared with eight (17.4%) pegfilgrastim 
treated patients (p=0.0018). No significant difference was seen in the number of 
patients needing intravenous antibiotics or platelet transfusions. Also, no differences 
were seen regarding the incidence of fever or the need for transfer to the intensive 
care unit between the two groups (Table 3). Overall treatment related mortality was 
0%. 
 
Cost analysis 
Cost analysis was performed using the Swiss drug prices listed for the year 
2008. The median cost per patient for filgrastim was 1979 Swiss francs, compared 
with 2077 Swiss francs for pegfilgrastim (p=0.25, Mann-Whitney U-test).  
An integrated cost analysis including the cost of the G-CSF used, the infused 
blood products and the hospital stay revealed that treatment cost were lower with 
pegfilgrastim than with filgrastim (p=0.031, Mann-Whitney U-test) with an additional 
expenditure of 1274 Swiss francs per patient (6%) in the filgrastim treated cohort. 
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Discussion 
Our objective was to assess the impact of pegfilgrastim on the clinical 
outcome of patients with multiple myeloma who received melphalan in a dose of 200 
mg/m2, since patients with different diseases may differ in terms of demographics, 
and conditioning regimens may also vary in terms of toxicity [21-23]. 
In this homogenous patient collective we observed that pegfilgrastim is able to 
reduce the duration of grade 4 neutropenia and, accordingly, the time to engraftment 
when compared with filgrastim.  
Furthermore, the length of hospital stay was reduced with pegfilgrastim. This 
finding may be directly associated with the reduced time to engraftment, since our 
patients are generally discharged when neutrophil recovery has been documented 
and no additional reasons for inpatient treatment are present. Interestingly, we could 
not observe a reduction in the incidence of fever and the need for intravenous 
antibiotics during the hospitalization. Although fever was documented in the majority 
of patients in both subgroups (72% and 63%, respectively), the duration of fever was 
similar and generally short lasting in both groups (median 2 days with filgrastim and 1 
day with pegfilgrastim, respectively), which may also explain the lack of a significant 
difference in the use of intravenous antibiotics. 
Filgrastim was administered for a median of 9 days per case, and therefore 
absolute treatment cost of the two G-CSF did not differ significantly between the two 
groups. In contrast, an integrated analysis including the cost of G-CSF applied, the 
cost of blood products and the daily cost of inpatient care at our clinic revealed that 
treatment with pegfilgrastim reduced the overall cost by 6% compared to filgrastim. 
The main reasons for this finding are probably the faster discharge of patients who 
received pegfilgrastim and the reduced need for blood products. 
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The latter observation is of particular interest as it is known that post-
transplant use of G-CSF may impair the recovery of other hematopoietic progenitors. 
Bensinger and collegues have suggested a steal phenomenon whereas myeloid 
progenitors may be favored over platelet progenitors by the use of G-CSF resulting in 
delayed platelet recovery [25]. Further evidence for such a mechanism comes from 
the use of G-CSF in congenital neutropenia where overstimulation of the neutrophilic 
compartment with pegfilgrastim has been reported to result in a thrombocytopenia 
among other adverse effects [26]. In our series, no delay in erythrocyte or 
thrombocyte recovery was observed with the fixed dose of pegfilgrastim, and the 
supposed better control of the hematopoiesis by using filgrastim appears not to be 
superior with regard to blood transfusions. The non-inferiority of pegfilgrastim with 
regard to this critical issue is therefore another important finding of this analysis. 
A few non-randomized retrospective analyses and small prospective studies 
have reported on this issue, but to our knowledge, this is the largest cohort in a 
homogenous patient collective analyzed so far to address this question [16-20]. A 
strength of this analysis is that patient care within our autologous transplantation 
program is highly regularized by standardized operating procedures and relevant 
clinical patient data is collected prospectively within our transplantation database. 
Further, by focussing on one entity and one standardized conditioning regimen any 
possible bias caused by the heterogeneity of patients and treatment modalities is 
minimized.  
In conclusion, considering the nature of this analysis - retrospective, single-
center design, superiority of pegfilgrastim in this setting can not be claimed, but 
equivalence of the two G-CSF formulations is highly probable.  
Pegfilgrastim appears to be at least comparable to filgrastim regarding the 
time to neutrophil engraftment, the length of hospital stay, the need for red blood cell 
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transfusions and the treatment cost in MM patients undergoing conditioning with 
Mel200 followed by APBSCT. No differences between the two G-CSF administered 
regarding incidence and duration of neutropenic fever, use of intravenous antibiotics 
and need for platelet transfusions were detectable. For confirmation of these data a 
randomized prospective trial with a sufficient and homogenous patient collective 
would be preferable. However, in the absence of definitive proof we provide clinicians 
with promising data regarding safety and equivalence of the application of pegylated 
G-CSF in autologous transplantation following Mel200 as conditioning regimen. 
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Tables 
Table 1: Patient characteristics (‘per transplant’ analysis). 
Parameter Filgrastim 
(n=46) 
Pegfilgrastim 
(n=46) 
P-Value 
Age 
Median – yr  
Range – yr  
 
56.5 
44 – 68.7 
 
57.9 
38 – 67.7 
 
 
0.82 
Gender 
Male – no. (%) 
Female – no. (%) 
 
22 (52) 
24 (48) 
 
32 (70) 
14 (30) 
 
 
0.056 
CD34+ cells reinfused 
median 
range 
 
3.2 
2.0 – 7.9 
 
3.2 
2.0 – 13.0 
 
 
0.51 
Number of APBSCT 
First APBSCT – no. (%) 
Second APBSCT – no. (%) 
 
31 (67) 
15 (33) 
 
36 (78) 
10 (22) 
 
 
0.35 
Myeloma type 
IgG – no. (%) 
IgA – no. (%) 
IgD – no. (%) 
Bence Jones – no. (%) 
Nonsecretory – no. (%) 
 
28 (61) 
7 (15) 
1 (2) 
8 (17) 
2 (4) 
 
27 (59) 
9 (19.5) 
0 (0) 
9 (19.5) 
1 (2) 
 
 
 
 
 
0.93 
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Table 2: Clinical outcomes in MM patients treated with Mel200.  
Parameter Filgrastim 
(n=46) 
Pegfilgrastim 
(n=46) 
P-Value 
Length of hospital stay 
Median – days 
Range – days 
 
15.5 
12 – 64 
 
14.5 
11 – 47 
 
 
0.024 
Time to Engraftment 
Median – days 
Range – days 
 
10 
8 – 12  
 
9 
8 – 18  
 
 
0.032 
Duration of neutropenia grade 4 
Median – days  
Range – days  
 
6 
3 – 9  
 
5 
3 – 14  
 
 
0.0079 
Duration of thrombocytopenia grade 4 
Median – days  
Range – days  
 
3 
0 – 10  
 
3.5 
0 – 15  
 
 
0.39 
Duration of fever 
Median – days  
Range – days  
 
2 
0 – 12  
 
1 
0 – 19  
 
 
0.13 
Duration of i.v. antibiotic treatment 
Median – days  
Range – days  
 
6 
0 – 22  
 
5.5 
0 – 36  
 
 
0.12 
Red blood cell transfusions 
Median – number 
Range – number 
 
0.5 
0 – 9  
 
0 
0 – 10  
 
 
0.00065 
Platelet transfusions 
Median – number  
Range – number 
 
1 
0 – 8  
 
1 
0 – 10  
 
 
0.92 
 
Data presented as median (range), p-values from Mann-Whitney U-test. i.v., 
intravenous. 
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Table 3: Clinical outcomes (binary) in MM patients treated with Mel200.  
Parameter Filgrastim 
(n=46) 
Pegfilgrastim 
(n=46) 
P-Value 
Intravenous antibiotics – no. (%)  41 (89) 37 (80) 0.38 
Incidence of fever – no. (%) 33 (72) 29 (63) 0.51 
Red blood cell transfusions – no. (%) 23 (50) 8 (74) 0.0018 
Platelet transfusions – no. (%) 36 (78) 34 (74) 0.81 
Transfer to ICU – no. (%) 3 (7) 2 (4) 1 
 
Data presented in absolute patient numbers and percent, p-values from Fisher’s 
exact test. ICU, intensive care unit. 
 
 
